# US 2025/0032593 A1 · Eukaryotic elongation factor-2 kinase as a cytotoxic t lymphocytes booster

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0032593 A1
- Document ID: US20250032593A1
- Status: Published application
- Kind: A1
- Application number: 18/716,884
- Filed: 2022-12-20
- Published: 2025-01-30
- Earliest claimed: 2021-12-20
- Assignees: The Texas A&M University System
- Applicants: The Texas A&M University System
- Inventors: Jianxun Jim Song
- Web page: https://patentgrep.com/patent/US20250032593A1

## CPC

- A61K 38/45: Transferases (2)
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- C12Y 207/1102: Elongation factor 2 kinase (2.7.11.20), i.e. eEF-2K
- A61P 35/00: Antineoplastic agents
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In an embodiment, the present disclosure pertains to a method of reducing cytocidal activity of cells. In some embodiments, the method includes altering eukaryotic elongation factor-2 kinase (eEF-2K) in a subject and inducing a reduction of cytocidal activity of cytotoxic T cells (CTLs) in the subject. In some embodiments, the altering of eEF-2K in the subject can include a decrease of eEF-2K in the subject.

## Claims

### Claim 1

A method of reducing cytocidal activity of cells, the method comprising:
altering eukaryotic elongation factor-2 kinase (eEF-2K) in a subject; and
inducing a reduction of cytocidal activity of cytotoxic T cells (CTLs) in the subject.

### Claim 2 (depends on 1)

The method of claim 1, further comprising regulating, by the altering of eEF-2K in the subject, stress responses or cellular metabolism in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the CTLs are CD8+ or CD4+ cells.

### Claim 4 (depends on 1)

The method of claim 1, further comprising inducing metabolic reprograming in the subject.

### Claim 5 (depends on 4)

The method of claim 4, further comprising controlling a function of immune cells in the subject selected from the group consisting of survival, differentiation, expansion, activation, and combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the altering of eEF-2K in the subject comprises ablation of eEF-2K and thereby results in an exhausted state of cytotoxic T cells in the subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein the altering of eEF-2K in the subject comprises an increase in phosphorylation of at least one of Akt, mTOR, or S6K to thereby deplete eEF-2K.

### Claim 8 (depends on 7)

The method of claim 7, wherein the depleted eEF-2k induces hyperactivation of Akt-mTOR-S6K signaling.

### Claim 9 (depends on 1)

The method of claim 1, wherein the altering of eEF-2K in the subject comprises a decrease of eEF-2K in the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the decrease reduces survival and function of cytotoxic T cells.

### Claim 11 (depends on 9)

The method of claim 9, wherein the decrease alters at least one of cell proliferation, premature cellular senescence, or exhaustion thereby reducing survival and function of cytotoxic T cells.

### Claim 12 (depends on 9)

The method of claim 9, wherein the decrease activates Akt-mTOR-S6K signaling and reprogrammed metabolism thereby reducing survival and function of cytotoxic T cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein Akt-mTOR-S6K signaling is caused by an uptake of heat shock protein 90.

### Claim 14 (depends on 12)

The method of claim 12, wherein Akt-mTOR-S6K signaling is caused by NF-κB activation.

### Claim 15 (depends on 1)

The method of claim 1, wherein the altering of eEF-2K in the subject comprises therapeutic augmentation of this kinase to reinforce chimeric antigen (Ag) receptor (CAR) T-cell therapy.

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject is being treated for cancer.

### Claim 17 (depends on 1)

The method of claim 1, wherein the subject is being treated for an infectious disease.

### Claim 18 (depends on 1)

The method of claim 1, wherein the altering of eEF-2K in the subject impairs activity of cytotoxic T cells in the subject.

### Claim 19 (depends on 1)

The method of claim 1, wherein the altering of eEF-2K in the subject impairs function of cytotoxic T cells in the subject.

### Claim 20 (depends on 1)

The method of claim 1, wherein the altering of eEF-2K in the subject reduces survival of cytotoxic T cells in the subject.
